---
title: Non Alcoholic Fatty Liver Disease Influence of Statin Therapy
nct_id: NCT00375349
overall_status: WITHDRAWN
phase: NA
sponsor: Shaare Zedek Medical Center
study_type: INTERVENTIONAL
primary_condition: Non-alcoholic Fatty Liver Disease (NAFLD)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00375349.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00375349"
ct_last_update_post_date: 2016-09-30
last_seen_at: "2026-05-12T07:30:48.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Non Alcoholic Fatty Liver Disease Influence of Statin Therapy

**NCT ID:** [NCT00375349](https://clinicaltrials.gov/study/NCT00375349)

## Key Facts

- **Status:** WITHDRAWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** Shaare Zedek Medical Center
- **Conditions:** Non-alcoholic Fatty Liver Disease (NAFLD)
- **Start Date:** 2006-09
- **Completion Date:** 2009-09
- **CT.gov Last Update:** 2016-09-30

## Brief Summary

Aim:

1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department.
2. To assess the effect of statins on the prevalence of fatty liver by a cross sectional survey of patients hospitalized with chest pain.

## Detailed Description

Consecutive patients hospitalized with chest pain will be recruited at the cardiology department. Patients with an inflammatory condition, recent infection or history of alcoholism will be excluded. After signing an informed consent each patient will undergo an ultrasound examination for diagnosis of fatty liver. Information regarding BMI, hypertension and use of medications will be collected on each patient. Blood samples for fasting glucose, hemoglobin A1C, lipid profile, ESR, and CRP and liver function tests will be collected from each participant. Prevalence of fatty liver in patients who have been taking statins for 6 months or more statins will be compared to patients who have been taking statins for a lesser period and to those who do have not taken statins using a multivariate regression analysis.

Serum samples will be frozen and kept for future ongoing research.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Cardiology patient
* Age above 18

Exclusion Criteria:

* Age below 18
```

## Interventions

- **Ultrasound to demonstrate existence of fatty liver** (PROCEDURE)

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00375349.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00375349*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*